{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T06:01:47Z","timestamp":1785132107161,"version":"3.55.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Multiple myeloma (MM) persists within a specialized bone marrow niche in which malignant plasma cells, immune dysfunction, inflammatory signaling, and metabolic stress reinforce one another. To resolve this ecosystem at compartment-level resolution, we integrated public single-cell RNA sequencing data with pathway scoring, cell-cell communication inference, independent clinical validation, multiplex immunofluorescence, and metabolic perturbation experiments. Analysis of 95,940 bone marrow cells identified 32 annotated populations and revealed broad microenvironmental remodeling in MM, including plasma-cell expansion, altered cytotoxic and dendritic-cell compartments, TAM-associated inflammatory programs, and lineage-specific hematopoietic perturbations. Hallmark pathway analysis identified recurrent immunometabolic programs, including IL6-JAK-STAT3, TNF\u03b1-NF\u03baB, mTORC1 signaling, oxidative phosphorylation, unfolded protein response, hypoxia, and checkpoint\/exhaustion-associated pathways. CellChat analysis showed disease-associated rewiring of ligand-receptor networks involving malignant plasma cells, TAMs, dendritic cells, and T\/NK subsets, with checkpoint-enriched communication and clinically relevant plasma-cell and CD274 survival associations. Serum IL-6 was elevated in an independent clinical validation cohort. Multiplex immunofluorescence confirmed PD-L1-positive plasma cells, C1QA\/C1QB\/C1QC-positive TAMs expressing LAG3, and CD8-positive\/LAG3-positive cytotoxic T cells. Mechanistically, malignant plasma cells showed transcriptional activation of LDH-associated glycolytic\/lactate programs and ASCT2\/SLC1A5-GLS-linked glutamine-metabolic programs, nominating these pathways as functional vulnerabilities. Accordingly, the LDH inhibitor galloflavin and the ASCT2\/SLC1A5 glutamine-transport inhibitor V-9302 suppressed RPMI-8226 viability in dose- and time-dependent manners; their combination produced synergistic anti-myeloma activity supported by Bliss synergy, combination-index analysis, observed-versus-expected inhibition, and apoptosis-related validation. Together, these findings support an IL6-centered immunometabolic communication circuit linking malignant plasma cells, TAMs, and dysfunctional T cells, and identify cooperative glycolytic\/lactate and glutamine-dependent metabolic vulnerabilities with therapeutic relevance in MM.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1734500","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:40:45Z","timestamp":1785130845000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Single-cell and functional profiling identifies an IL6-centered immunometabolic communication circuit in multiple myeloma"],"prefix":"10.3389","volume":"17","author":[{"given":"Delong","family":"Lang","sequence":"first","affiliation":[{"name":"Department of Hematology, Fuyang People\u2019s Hospital (The Affiliated Fuyang People\u2019s Hospital of Anhui Medical University)","place":["Fuyang, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayou","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhu","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fuyang People\u2019s Hospital (The Affiliated Fuyang People\u2019s Hospital of Anhui Medical University)","place":["Fuyang, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1077768","article-title":"Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma","volume":"13","author":"Lv","year":"2022","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-021-00440-4","article-title":"Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and Malignant cell-mediated immunosuppression","volume":"11","author":"Visram","year":"2021","journal-title":"Blood Cancer J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061682","article-title":"Metabolic alterations in multiple myeloma: from oncogenesis to proteasome inhibitor resistance","volume":"15","author":"Weir","year":"2023","journal-title":"Cancers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.591342","article-title":"Metabolic reprogramming induces immune cell dysfunction in the tumor microenvironment of multiple myeloma","volume":"10","author":"Wu","year":"2020","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1132","article-title":"Identification of the immune checkpoint signature of multiple myeloma using mass cytometry-based single-cell analysis","volume":"9","author":"Wang","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-gamma and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-825240","article-title":"Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade","volume":"132","author":"Minnie","year":"2018","journal-title":"Blood"},{"key":"B8","article-title":"Targeting the tumor microenvironment: JAK-STAT3 signaling","volume":"2","author":"Bournazou","year":"2013","journal-title":"Jakstat"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v74.1.11.11","article-title":"Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma","volume":"74","author":"Zhang","year":"1989","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114392","article-title":"Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias","volume":"84","author":"Bataille","year":"1989","journal-title":"J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","article-title":"Inference and analysis of cell-cell communication using CellChat","volume":"12","author":"Jin","year":"2021","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.844604","article-title":"Cellular interaction analysis characterizing immunosuppressive microenvironment functions in MM tumorigenesis from precursor stages","volume":"13","author":"Liu","year":"2022","journal-title":"Front Genet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0914433107","article-title":"Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression","volume":"107","author":"Le","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B14","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nm.4464","article-title":"Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models","volume":"24","author":"Schulte","year":"2018","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201100471","article-title":"Galloflavin (CAS 568-80-9): a novel inhibitor of lactate dehydrogenase","volume":"7","author":"Manerba","year":"2012","journal-title":"ChemMedChem"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-690743","article-title":"Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target","volume":"128","author":"Bolzoni","year":"2016","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.464","article-title":"Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax","volume":"35","author":"Bajpai","year":"2016","journal-title":"Oncogene"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3400","article-title":"Metabolic signature identifies novel targets for drug resistance in multiple myeloma","volume":"75","author":"Maiso","year":"2015","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20691","article-title":"Glutaminase inhibition in multiple myeloma induces apoptosis via MYC degradation","volume":"8","author":"Effenberger","year":"2017","journal-title":"Oncotarget"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19041200","article-title":"Metabolic features of multiple myeloma","volume":"19","author":"El Arfani","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.897862","article-title":"Multiple myeloma metabolism - a treasure trove of therapeutic targets","volume":"13","author":"Roman-Trufero","year":"2022","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1141851","article-title":"Shutting off the fuel supply to target metabolic vulnerabilities in multiple myeloma","volume":"13","author":"Rana","year":"2023","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.71","article-title":"From Krebs to clinic: glutamine metabolism to cancer therapy","volume":"16","author":"Altman","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The emerging hallmarks of cancer metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab"},{"key":"B25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40164-022-00303-z","article-title":"Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma","volume":"11","author":"Oudaert","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-022-02398-4","article-title":"FOXM1 regulates glycolysis and energy production in multiple myeloma","volume":"41","author":"Cheng","year":"2022","journal-title":"Oncogene"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1155621","article-title":"Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment","volume":"13","author":"Matamala Montoya","year":"2023","journal-title":"Front Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-347484","article-title":"Multiple myeloma-related deregulation of bone marrow-derived CD34-positive hematopoietic stem and progenitor cells","volume":"120","author":"Bruns","year":"2012","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001390","article-title":"LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma","volume":"4","author":"Keane","year":"2020","journal-title":"Blood Adv"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2133543","article-title":"The enigma of LAG3 receptor in hematological Malignancies","volume":"63","author":"Kreiniz","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/pro.70032","article-title":"The multifaceted role of XCL1 in health and disease","volume":"34","author":"Syed","year":"2025","journal-title":"Protein Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1370854","article-title":"Targeted therapy for multiple myeloma: an overview on CD138-based strategies","volume":"14","author":"Riccardi","year":"2024","journal-title":"Front Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s12308-012-0166-4","article-title":"FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma","volume":"6","author":"Danilova","year":"2013","journal-title":"J Hematop"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112766","article-title":"mTORC1 inhibition potentiating metabolic block by tyrosine kinase inhibitor ponatinib in multiple myeloma","volume":"14","author":"Nazim","year":"2022","journal-title":"Cancers"},{"key":"B35","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41419-022-05421-4","article-title":"An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma","volume":"13","author":"Darawshi","year":"2022","journal-title":"Cell Death Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1734500\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:40:46Z","timestamp":1785130846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1734500\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2026.1734500"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1734500","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"article-number":"1734500"}}